Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: May 2010

Welcome to the new Biopharmconsortium Blog!

TweetHaberman Associates’ Biopharmconsortium Blog, formerly at http://biopharmconsortium.blogspot.com, has moved to our own site. You can now find it at http://biopharmconsortium.com/blog/blog. If you’re here, you have obviously found the new site. Welcome! Our new site is now also powered by WordPress. We hope that you like the new format, and the WordPress features. We are new…

A frog jumps into the animal model lineup

TweetThe cover of the 30 April 2010 issue of Science bears a photo of a tadpole of the western clawed frog Xenopus tropicalis. In that issue is a report on the draft sequence of the genome of this organism, and a short companion news feature. The report on the genome emphasizes X. tropicalis’ role as…

More on anti-aging research: Continuing controversy, opportunity, and good news

Tweet 1. Continuing Controversy In our blog post on 10 February 2010, we discussed the controversy over Sirtris/GlaxoSmithKline’s reseveratrol formulation, and its second-generation sirtuin-1 (SIRT1) activators. Researchers at Amgen and Pfizer found that the apparent in vitro activation of SIRT1 by these compounds was an artifact of the experimental method used by Sirtris researchers. The…